Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

“…15,77 In the earlier studies, 8MOP was administered orally, but this practice has now been replaced by ex vivo admixture of 8MOP prior to UV administration. 15,77 The procedure has been described in detail by Knobler and Jantschitsch 77 ECP is usually performed on two successive days every 4 weeks.…”

“…15,77 In the earlier studies, 8MOP was administered orally, but this practice has now been replaced by ex vivo admixture of 8MOP prior to UV administration. 15,77 The procedure has been described in detail by Knobler and Jantschitsch 77 ECP is usually performed on two successive days every 4 weeks. 8,15 The schedule is generally continued for up to 6 months in order to assess response: maintenance therapy is tailored according to disease course.…”

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

“…While responses vary between case series, overall response rates hover around 60%, with a complete response rate of 20% [310,311]. As current treatment protocols no longer require the oral administration of 8-MOP, eliminating nausea, ECP is safe and generally very well tolerated.…”

“…It is not surprising then that the median time to response following the initiation of ECP is 6 months. Median survival exceeding 8 years has been observed in ECP treated patients and among complete responders, many experience durable responses which may permit, for some, weaning from CTCL-directed therapies [310,[312][313][314]. While patient-or disease-specific factors which may predict a response to therapy are imperfect, patients for whom treatment is initiated promptly after diagnosis who have circulating Sé zary cells, but without significant nodal or visceral disease, may be more likely to respond.…”

“…While patient-or disease-specific factors which may predict a response to therapy are imperfect, patients for whom treatment is initiated promptly after diagnosis who have circulating Sé zary cells, but without significant nodal or visceral disease, may be more likely to respond. In addition, patients without profound immune deficiencies, reflected by normal or near-normal cytotoxic T-cell and CD4/CD8 values and the absence of prior exposure to systemic chemotherapy, may be more likely to respond to therapy [310,313]. While effective as monotherapy, ECP has also been combined with other therapeutic strategies, including interferon, bexarotene and TSEBT [292,302,312,[315][316][317].…”